Lapatinib-d4 is a deuterium-labeled variant of Lapatinib. It functions as a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains, with IC50 values of 10.2 nM for purified EGFR and 9.8 nM for ErbB-2. Stable heavy isotopes, including deuterium, are incorporated into drug molecules primarily for quantitation during drug development, and deuterium substitution can influence the pharmacokinetic and metabolic profiles of drugs. This compound is intended for research use only and is not sold to patients.
- Can be used as a tracer.
- Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
- Deuteration can affect the pharmacokinetic and metabolic profiles of drugs.